Applied DNA Announces Pricing of $12 Million Public Offering
Applied DNA Sciences (NASDAQ: APDN) announced the pricing of a public offering expected to generate approximately $12 million in gross proceeds. The offering includes 9,230,769 units, each consisting of a common share or pre-funded warrant, a Series A Warrant, and a Series B Warrant. Series A Warrants are exercisable at $1.99 per share and expire on the fifth anniversary of stockholder approval, while Series B Warrants also have an exercise price of $1.99 but expire one year after stockholder approval. The offering price per unit with a common share is $1.30. Net proceeds will support development of DNA production and MDx testing services, along with general corporate purposes. The offering is expected to close on May 29, 2024, subject to customary conditions. Craig-Hallum and Laidlaw & Company (UK) are acting as placement agents.
- Expected gross proceeds of approximately $12 million.
- Net proceeds to support development of Therapeutic DNA Production Services and MDx Testing Services.
- Offering price per unit with a common share set at $1.30, potentially appealing to investors.
- Issuance of 9,230,769 units could lead to shareholder dilution.
- Series A and B Warrants have an exercise price of $1.99, higher than the current unit price, which may deter immediate exercising.
- Potential dilution from the exercise of Series A and B Warrants in the future.
From a financial perspective, Applied DNA's $12 million public offering is a noteworthy event, as it significantly impacts the company's cash flow and financial strategy. The offering includes a blend of common shares and pre-funded warrants with various exercise terms. This type of structure can be a strategic move to attract a wider range of investors by offering flexibility in investment.
The funds raised are earmarked for diverse purposes including further development of the company's therapeutic DNA production services and MDx testing services, which are core to Applied DNA's business model. Additionally, the company has the flexibility to use these funds for R&D, capital expenditures and potential acquisitions, which provides growth opportunities and flexibility. However, it's important to note the exercise price of the warrants ($1.99) compared to the offering price per unit ($1.30) may indicate management's confidence in future growth but also presents a threshold that must be reached or exceeded for warrant holders to benefit.
For retail investors, understanding the potential dilution effect of new shares and the future cash flows from warrant exercises is crucial. The dilution can impact existing shareholders' value, but the infusion of capital is intended to foster growth and potentially enhance long-term shareholder value.
The rating for this PR is
From a market perspective, the public offering by Applied DNA indicates the company's strategy to tap into the capital markets to fuel its growth. The inclusion of pre-funded warrants and two types of warrants (Series A and Series B) with different exercise terms shows a versatile approach to attract various investor profiles. The pre-funded warrants, often used to remove barriers for certain investors (e.g., those with limitations on the number of shares they can hold), allow the company to broaden its investor base.
Additionally, the offering's structure, with Series A warrants having a five-year term and Series B warrants a one-year term, provides both short-term and long-term investment opportunities, potentially aligning with different investor strategies. The flexibility in warrant exercise options (cashless vs. cash) can also make the investment more attractive.
It's worth noting that the proceeds are intended for growth-related expenditures, including R&D and potential acquisitions. These are areas that can significantly enhance the company's competitive position in the PCR-based DNA technology market. However, the absence of specific commitments for acquisitions or investments may suggest a focus on organic growth for now, which can be both a safe and conservative approach. For retail investors, understanding the strategic use of proceeds and the potential impact on the company's market position is key.
The rating for this PR is
STONY BROOK, NY / ACCESSWIRE / May 28, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a public offering with gross proceeds to the Company expected to be approximately
The offering is comprised of 9,230,769 Units with each Unit consisting of (i) either (A) one share of common stock ("Common Share") or (B) one pre-funded warrant (the "Pre-Funded Warrant") to purchase one Common Share; (ii) one Series A Warrant to purchase one Common Share at an exercise price of
The purchase price of each Unit with a Common Share is
Applied DNA intends to use the net proceeds from this offering to further develop its Therapeutic DNA Production Services and MDx Testing Services, as well as for general corporate purposes. Applied DNA may also use a portion of the net proceeds for research and development expenses, capital expenditures, working capital and general and administrative expenses, or to fund potential acquisitions of or investments in businesses, products and technologies that complement its business; however, Applied DNA has no present commitments or agreements to make any such acquisitions or investments. This offering is expected to close on or about May 29, 2024, subject to satisfaction of customary closing conditions.
Craig-Hallum is acting as lead placement agent and Laidlaw & Company (UK) Ltd. is acting as co-placement agent for the offering.
The securities described above are being offered by Applied DNA pursuant to a registration statement on Form S-1 (File No. 333-278890) previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a written preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Alternatively, when available, copies of the final prospectus relating to this offering may be obtained from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, by telephone at (612) 334-6300 or by email at prospectus@chlm.com; or from Laidlaw & Company (UK) Ltd., Attention: Syndicate Department, 521 Fifth Avenue, 12th Floor, New York, NY 10175, or by email at syndicate@laidlawltd.com.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the substantial doubt about its ability to continue as a going concern, Applied DNA's ability to satisfy customary closing conditions for the offering, its unknown ability to satisfy all Nasdaq listing requirements, the unknown future demand for its biotherapeutics products and services, its unknown ability to procure additional financing to build incremental GMP manufacturing facility, the unknown amount of revenues and profits that will result from its Linea IVT and or Linea DNA platforms, limited market acceptance for its supply chain security products and services, the declining demand for Applied DNA's COVID-19 testing services, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, the risk that the offering described herein may not close, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023 and Quarterly Report on Form 10-Q filed on February 8, 2024 and May 10, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Contacts:
Applied DNA Sciences
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN
SOURCE: Applied DNA Sciences, Inc.
View the original press release on accesswire.com
FAQ
What is the stock symbol for Applied DNA Sciences?
How much is Applied DNA Sciences expected to raise from the public offering?
What does each unit of the Applied DNA Sciences public offering consist of?
What is the exercise price for the Series A Warrants offered by Applied DNA Sciences?
When is the Applied DNA Sciences public offering expected to close?
What will Applied DNA Sciences use the net proceeds from the offering for?
